Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11858672 | 0.98 | CRBN (0.32) | CRBN | |
| SCHEMBL5858590 | 0.90 | — | — | |
| SCHEMBL26685924 | 0.78 | CRBN (0.36) | CRBN | |
| SCHEMBL6833316 | 0.78 | CRBN (0.50) | CRBN | |
| SCHEMBL4986868 | 0.76 | CRBN (0.44) | CRBN | |
| SCHEMBL26686283 | 0.75 | — | — | |
| SCHEMBL29749879 | 0.73 | CRBN (0.50) | CRBN | |
| SCHEMBL25330146 | 0.70 | CRBN (0.47) | CRBN | |
| SCHEMBL1502960 | 0.70 | CRBN (0.42) | CRBN | |
| Hydrochloric Acid SCHEMBL19817283 | 0.70 | CRBN (0.42) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149021-B2 | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| US-20200071302-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-03-05 | — | — | US | disclosed |
| US-3994914-A | INTERMEDIATES IN SYNTHESIS OF HYPOTENSIVE AZETIDINONES | ELI LILLY AND COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071302-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | CSF1R, CSF3R, FAR1 | CRBN 615/4885 |
| US-11149021-B2 | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | CSF1R, CSF3R, FAR1 | CRBN 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.